Previous 10 | Next 10 |
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors PR Newswire WALTHAM, Mass. , May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of...
2024-05-14 04:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference PR Newswire WALTHAM, Mass. , May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeli...
2024-05-08 16:08:09 ET Syndax Pharmaceuticals, Inc. (SNDX) Q1 2024 Earnings Conference Call May 08, 2024, 08:00 ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - CEO & Director Steve Closter - Chief Commercial Officer Keit...
2024-05-08 07:23:29 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript Crine...
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update PR Newswire – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 ȁ...
2024-05-07 14:09:48 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript Crine...
2024-05-04 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 PR Newswire WALTHAM, Mass. , May 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an in...
2024-04-24 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress PR Newswire - Data continue to support revumenib's potential to enhance current standard of care agents - ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...